Alternatives to Humalog

Rapid-Acting Insulin Analogue Alternatives

The American Diabetes Association guidelines explicitly group insulin lispro, insulin aspart, and insulin glulisine together as interchangeable options for prandial coverage, with the same rapid onset, peak action, and duration 1, 2, 3
Insulin aspart and insulin glulisine are the preferred alternatives to Humalog, as they share the same rapid onset, peak action, and duration, and provide superior postprandial glucose control compared to regular human insulin 4, 1, 2, 3

Regular human insulin is a more affordable alternative to rapid-acting analogues, but requires administration 30 minutes before meals and has a longer duration of action, increasing the risk of delayed hypoglycemia between meals 4, 1
The American College of Clinical Endocrinologists recommends considering regular human insulin for patients facing cost barriers, despite its limitations, due to its lower cost, approximately $46 per 10mL vial compared to $78-84 for rapid-acting analogues 4

The American Diabetes Association recommends ensuring appropriate basal insulin coverage when optimizing prandial insulin therapy, with options including NPH, glargine, detemir, or degludec, each with its own advantages and disadvantages 1, 2, 3
NPH insulin is the most affordable basal option, but has a peak action that increases hypoglycemia risk, whereas long-acting analogues have more consistent absorption and lower hypoglycemia rates, but cost more 4, 1

The American Association of Clinical Endocrinologists recommends adding a GLP-1 receptor agonist instead of prandial insulin as an alternative strategy to minimize hypoglycemia and weight gain, particularly when basal insulin exceeds 0.5 units/kg/day without achieving glycemic targets 1, 5
GLP-1 receptor agonists address postprandial hyperglycemia while avoiding the weight gain and hypoglycemia risk associated with prandial insulin, and are a beneficial option for patients requiring intensification beyond basal insulin 1, 5

The cost of Aspart U-100 prefilled pen is $224, according to data from 2024 6
The cost of Glulisine U-100 prefilled pen is $439, based on median costs per 1,000 units from 2023 data 6
The cost of Aspart U-100 vial is $174, with the prefilled pen option costing $224, as reported in Diabetes Care in 2024 6